Evidence map›Paper›PMID 23284886›Full record

ArticlePloS one2012

Population distribution of Beta-lactamase conferring resistance to third-generation cephalosporins in human clinical Enterobacteriaceae in the Netherlands.

Guido M Voets, Tamara N Platteel, Ad C Fluit, Jelle Scharringa, Claudia M Schapendonk, James Cohen Stuart, Marc J M Bonten, Maurine A Leverstein-van Hall, Maurine A L Hall, National ESBL Surveillance Working Group

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 59 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Detection and genotype analysis of AmpC β-lactamase inExperimental and therapeutic medicine · 2016
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Escherichia coli ST131, an intriguing clonal group.Clinical microbiology reviews · 2014
    Review
  18. Long-term dissemination of acquired AmpC β-lactamases among Klebsiella spp. and Escherichia coli in Portuguese clinical settings.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2014
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

  • Erratum issued
    Hall, Maurine A L [corrected to Leverstein-van Hall, Maurine A]
5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Guido M VoetsDepartment of Medical Microbiology, University Medical Centre Utrecht, Utrecht, The Netherlands. g.voets@umcutrecht.nl
Tamara N Platteel
Ad C Fluit
Jelle Scharringa
Claudia M Schapendonk
James Cohen Stuart
Marc J M Bonten
Maurine A Leverstein-van Hall
Maurine A L Hall
National ESBL Surveillance Working Group
University Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a global increase in infections caused by Enterobacteriaceae with plasmid-borne β-lactamases that confer resistance to third-generation cephalosporins. The epidemiology of these bacteria is not well understood, and was, therefore, investigated in a selection of 636 clinical Enterobacteriaceae with a minimal inhibitory concentration >1 mg/L for ceftazidime/ceftriaxone from a national survey (75% E. coli, 11% E. cloacae, 11% K. pneumoniae, 2% K. oxytoca, 2% P. mirabilis). Isolates were investigated for extended-spectrum β-lactamases (ESBLs) and ampC genes using microarray, PCR, gene sequencing and molecular straintyping (Diversilab and multi-locus sequence typing (MLST)). ESBL genes were demonstrated in 512 isolates (81%); of which 446 (87%) belonged to the CTX-M family. Among 314 randomly selected and sequenced isolates, bla(CTX-M-15) was most prevalent (n = 124, 39%), followed by bla(CTX-M-1) (n = 47, 15%), bla(CTX-M-14) (n = 15, 5%), bla(SHV-12) (n = 24, 8%) and bla(TEM-52) (n = 13, 4%). Among 181 isolates with MIC ≥16 mg/L for cefoxitin plasmid encoded AmpCs were detected in 32 and 27 were of the CMY-2 group. Among 102 E. coli isolates with MIC ≥16 mg/L for cefoxitin ampC promoter mutations were identified in 29 (28%). Based on Diversilab genotyping of 608 isolates (similarity cut-off >98%) discriminatory indices of bacteria with ESBL and/or ampC genes were 0.994, 0.985 and 0.994 for E. coli, K. pneumoniae and E. cloacae, respectively. Based on similarity cut-off >95% two large clusters of E. coli were apparent (of 43 and 30 isolates) and 21 of 21 that were typed by belonged to ST131 of which 13 contained bla(CTX-M-15). Our findings demonstrate that bla(CTX-M-15) is the most prevalent ESBL and we report a larger than previously reported prevalence of ampC genes among Enterobacteriaceae responsible for resistance to third-generation cephalosporins.

Indexed as

AdolescentAdultAgedAnti-Bacterial AgentsBacterial ProteinsBacterial Typing Techniquesbeta-LactamasesCephalosporin ResistanceCephalosporinsChildChild, PreschoolEnterobacteriaceaeHumansInfantInfant, NewbornMicrobial Sensitivity TestsAmpC beta-lactamasesAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCephalosporins

Identifiers

PMID23284886
PMCPMC3527366
OpenAlexW2028740412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.